New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
09:00 EDTXOMAXOMA Phase III gevokizumab trial likely to miss endpoint, says Summer Street
Summer Street believes Xoma's Phase III trial for gevokizumab will likely not meet the primary endpoint of being effective in treating eye involvement in patients with BehÁetís disease. The firm says prior clinical trials indicate that the product is only a weak anti-inflammatory agent.
News For XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for XOMA

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use